Wednesday, 05 October 2022


Daiichi, Sanofi seeks nod for baby vaccine in Japan

21 February 2013 | News | By BioSpectrum Bureau

Tetravalent DPT-IPV vaccine combines Kitasato Daiichi Sankyo DPT vaccine and Sanofi Pasteur enhanced inactivated Salk poliomyelitis vaccine

Tetravalent DPT-IPV vaccine combines Kitasato Daiichi Sankyo DPT vaccine and Sanofi Pasteur enhanced inactivated Salk poliomyelitis vaccine

Singapore: Kitasato Daiichi Sankyo, a member of the Daiichi Sankyo Group, has applied for approval of its tetravalent combination DPT-IPV vaccine in Japan for the prevention of diphtheria, pertussis (whooping cough), tetanus, and acute poliomyelitis (polio).

DPT-IPV vaccine, which is supplied in pre-filled syringes, combines DPT vaccine from Kitasato Daiichi Sankyo and the enhanced inactivated Salk poliomyelitis vaccine (eIPV) from Sanofi Pasteur.

The Daiichi Sankyo Group and Sanofi Pasteur contribute to the protection and improvement of people's health and hygiene and the enhancement and dissemination of preventive medicine in Japan by supplying vaccines that meet unmet medical needs.

Sign up for the editor pick and get articles like this delivered right to your inbox.

Editors Pick
+Country Code-Phone Number(xxx-xxxxxxx)


Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account